AYLA

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ayala Pharmaceuticals (AYLA - Research Report), with a price target of $12.00. The company's shares closed last Friday at $1.39.According to TipRanks, Selvaraju is an analyst with an average return of -31.5% and a 19.50% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Brainsway, and Aeterna Zentaris.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ayala Pharmaceuticals with a $11.50 average price target, a 727.34% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-ayala-pharmaceuticals-ayla?utm_source=advfn.com&utm_medium=referral